This mini-review summarizes the current knowledge of IBD-CRC, focusing on the main mechanisms underlying its pathogenesis, and on the important role of immunomodulators and biologics used to treat IBD patients in interfering with the …

IBD发生CRC的风险是正常人群的2~4倍，约20%的IBD患者在发病10年内发生CRC，IBD发生癌变的平均病程为12年。 病程10年、20年、30年的UC患者发生癌变的比率分别为2%、8%、18%，CD患者数据与此相似。

Inflammatory bowel disease (IBD)-related colorectal cancer (CRC) is responsible for approximately 2% of the annual mortality from CRC overall, but 10-15% of the annual deaths in IBD patients. IBD-related CRC patients are also affected at a younger age than sporadic CRC patients, and have a 5-year su …

2016年10月18日 · 伴异型增生，特别是重度异型增生的 UC 患者 CRC 发生风险最高（3 级）；推荐对 IBD 患者进行内镜监测及根据患者的危险因素进行个体化治疗（1 级）；结直肠切除术能阻止 CRC 发生，但不能减少肛管、直肠袖口及储袋部位发生恶性肿瘤风险。

Chronic inflammation in patients with Inflammatory Bowel Disease (IBD) leads to an increased risk of colorectal cancer, small bowel cancer, intestinal lymphoma and cholangiocarcinoma. However, treatments for IBD have also been associated with an increased risk of neoplasms.

2023年11月9日 · 本研究旨在研究英国国家卫生服务 (NHS)中IBD-CRC患者的特征、 手术治疗 和结果。 利用CRC数据库中来自英国国家卫生服务体系 (English National Health Service)的人群数据，我们确定了2005-2018年有和无既往 诊断 IBD (克罗恩病、 溃疡性结肠炎 、未分类的IBD和伴 胆管 炎的IBD)的所有CRC。 采用描述性分析和logistic回归模型比较2组患者的特征及其2年转归。 本研究纳入了399614例诊断为CRC的患者，其中5141例 (1.3%)之前也曾被诊断为IBD。 IBD …

Patients with inflammatory bowel disease (IBD) are at significantly increased risk of colorectal cancer (CRC), principally resulting from the pro-neoplastic effects of chronic intestinal inflammation. Epidemiologic studies continue to highlight the increased risk of CRC in IBD.

2012年8月7日 · This review examines the literature relating to IBD-CRC, focusing on the incidence of IBD-CRC and examining potential risk factors including age at diagnosis, gender, duration and extent of colitis, severity of inflammation, family history of sporadic CRC and co-existent primary sclerosing cholangitis (PSC).

2021年12月18日 · The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases predisposes to the development of inflammatory bowel disease-associated colorectal cancer [IBD-CRC]. Inflammation can induce mutagenesis, and the relapsing-remitting nature of this inflammation, together with …

Inflammatory bowel disease (IBD) is widely accepted as one of the important risk factors leading to colorectal cancer (CRC). IBD ranks as the third highest risk condition for CRC, behind only familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer …